Viking Therapeutics Inc (VKTX)

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy AdultsJune 24, 2026 7:05 AM
PR Newswire (US) Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019Potential to further expand Viking's treatment options for weight lossSAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). VK3019 is being developed as a potential treatment option for weight loss. The study initiation follows the filing and clearance of VK3019's investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). The Phase 1 trial is a randomized, double-blind, placebo-controlled SAD study in healthy adults with BMI ≥30. The primary objectives of the study include evaluating the safety, tolerability, and pharmacokinetics of single subcutaneous doses of VK3019. Exploratory pharmacodynamic assessments include evaluations of changes in body weight after a single-dose administration. "The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians," said Brian Lian, Ph.D., chief executive officer of Viking. "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management. Given the complexity of managing obesity and related metabolic conditions, broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss."Preclinical data from Viking's internally developed DACRAs showed impressive effects on body weight, food intake, and metabolism in healthy rats and diet-induced obese (DIO) mice compared to control-treated animals. Results showed Viking's DACRAs reduced food intake in lean rats within 0 to 72 hours after a single dose. At 72 hours, these compounds reduced body weight by up to 8% compared to controls.  In addition to the Phase 1 trial of VK3019, Viking is currently conducting the Phase 3 VANQUISH studies of subcutaneous VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in patients with obesity or who are overweight. The VANQUISH program consists of two trials evaluating VK2735: one in adults with obesity (VANQUISH-1), and another in adults with obesity and type 2 diabetes (VANQUISH-2). Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.In parallel with the development of a subcutaneous formulation, Viking is advancing an oral tablet formulation of VK2735. If successful, oral VK2735 would represent the first oral dual agonist to reach the market. The company believes the availability of both oral and injectable formulations is a key differentiating feature of VK2735, compared with competitive agents, as no other dual or triple agonist is currently available in both formulations. Using the same active ingredient across formulations may also reduce the risk of unexpected side effects compared with switching between therapies that do not share the same active agent.  The company plans to initiate a Phase 3 trial to evaluate oral VK2735 for the treatment of obesity and overweight later this year.Based on VK2735's promising efficacy and differentiated pharmacokinetic (PK) profile, the company is evaluating a range of novel dosing regimens for both the induction and the long-term maintenance of weight loss. In October 2025, Viking initiated a Phase 1 study designed to explore the feasibility of various VK2735 maintenance dosing regimens.  Providing flexible dosing options for long-term therapy may improve treatment persistence following achievement of individual weight loss goals. The company believes this may lead to improved adherence to therapy and increase the probability of realizing the long-term benefits of weight loss, such as reduced cardiovascular risks, improved physical function, and enhanced quality of life.  The company expects to report the results of the study in 3Q26.About VK3019VK3019 is an investigational dual amylin and calcitonin receptor agonist (DACRA) in development as a potential new treatment option for weight loss.  It is currently being evaluated in a single ascending dose study assessing safety, tolerability, and pharmacokinetics of VK3019 for the treatment of metabolic disorders and obesity.About Amylin and CalcitoninAmylin and calcitonin receptors play an important role in food intake and metabolic control. Amylin is a peptide hormone co-secreted with insulin from pancreatic ß-cells that slows gastric emptying and suppresses postprandial glucagon secretion, promoting satiety and regulating blood glucose. After a meal, amylin is secreted from the pancreas and circulates in the blood to activate specific receptors in the brainstem. This results in suppression of glucagon release from the pancreas, reduced food intake, and slowed gastric emptying. The net effect of these actions is to decrease blood glucose and is associated with longer-term reductions in body weight. Calcitonin is a peptide hormone produced by the thyroid gland known for its role in regulating calcium homeostasis. To date, the addition of calcitonin receptor activation by DACRAs has demonstrated additional metabolic benefits not seen with amylin receptor activation alone, such as improved fasting glucose regulation and insulin sensitivity, and can result in a more acute reduction of food intake and greater body weight loss. About GLP-1 and Dual GLP-1/GIP AgonistsActivation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®.About Viking Therapeutics, Inc.Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.Forward-Looking StatementsThis press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK3019, VK0214, VK2809, and the company's other incretin and other receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings.  These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-novel-amylin-receptor-agonist-vk3019-in-healthy-adults-302808417.htmlSOURCE Viking Therapeutics, Inc. Original: Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical OfficerJune 11, 2026 7:05 AM
PR Newswire (US) Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Hubert C. Chen, M.D., as chief medical officer.  Dr. Chen brings more than two decades of leadership experience in senior executive roles spanning drug discovery, clinical development, regulatory strategy, and product approvals across multiple therapeutic areas.  Dr. Chen will report to Brian Lian, Ph.D., president and chief executive officer of Viking Therapeutics, and oversee clinical development, medical, and regulatory affairs. "We are thrilled to welcome Hubert to Viking as we move our next-generation therapies through late-stage development and prepare for VK2735's potential commercialization," said Brian Lian, Ph.D., president and chief executive officer of Viking Therapeutics. "He is an accomplished physician, scientist, and biotechnology executive with an impressive combination of scientific, clinical, regulatory, and operational expertise, along with extensive knowledge of obesity, metabolic disorders, and endocrinology. With multiple clinical programs advancing, this is a critical time to expand Viking's leadership team. Hubert's proven track record and history of developing innovative therapies make him an excellent addition to the team."Prior to joining Viking, Dr. Chen served as chief research and development officer at Loyal Animal Health, where he led the first-ever FDA-negotiated effectiveness and safety requirements for longevity therapeutics. Previously, he was president and chief scientific officer at Forte Biosciences, chief medical officer at Metacrine, and chief scientific and medical officer at Pfenex. At Pfenex, he developed a novel clinical and regulatory strategy for Bonsity, a drug-device combination for high-risk osteoporosis, leading to approvals in the U.S. and E.U. Earlier in his career, Dr. Chen led obesity and type 2 diabetes programs at Amylin Pharmaceuticals, including combinatorial approaches using glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and amylin analogs."Joining the Viking team at this exciting time of growth is an incredible opportunity, as obesity and metabolic disorders are among the most significant health challenges of our time, affecting nearly every aspect of long-term health and well-being," said Dr. Chen.  "Viking's scientific rigor and innovation have enabled the company to become a leader in this field, with a strong pipeline aimed at overcoming the challenges of achieving and maintaining significant weight loss and the associated health benefits. I look forward to working with the Viking team to make meaningful improvements in people's health and lives as we advance these important therapies."Dr. Chen earned his M.D. from Columbia, completed his internal medicine residency at Massachusetts General Hospital, and his endocrinology fellowship at the University of California, San Francisco. He has an undergraduate degree from Stanford and is an affiliate faculty at the University of California, San Diego.About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.Forward-Looking StatementsThis press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin and other receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-announces-appointment-of-hubert-c-chen-md-as-chief-medical-officer-302797455.htmlSOURCE Viking Therapeutics, Inc. Original: Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

an Viking Therapeutics Replicate Eli Lilly’s Success in the Weight-Loss Drug Market?

https://nai500.com/blog/2026/05/can-viking-therapeutics-replicate-eli-lillys-success-in-the-weight-loss-drug-market/

Good luck and GOD bless,

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesMay 13, 2026 9:00 AM
InvestorsHub NewsWireNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesBioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus ("T2DM") rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (Profile), which through its subsidiary GlucaPharm Inc. is developing a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history. SureNano is one of the emerging microcap companies active in the GLP-1 space, operating alongside established leaders including Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Viking Therapeutics Inc. (NASDAQ: VKTX) and Altimmune Inc. (NASDAQ: ALT).SureNano Science is developing GEP-44 as a patented next-generation metabolic therapy designed to address the limitations of first-generation GLP-1 drugs.The commercial potential tied to GLP-1 therapies is expanding quickly, with the global GLP-1 market forecast to potentially reach $190 billion by 2035.SureNano Science is also eyeing differentiated drug-delivery technologies designed to improve patient accessibility and long-term adherence.Preclinical data from SureNano Science suggest that GEP-44 may offer substantive differentiation relative to earlier-generation GLP therapies.Beyond its primary GLP-1 metabolic platform, SureNano Science is also evaluating early-stage opportunities that could expand the long-term scope of its therapeutic and delivery technology portfolio.Click here to view the custom infographic of the SureNano Science editorial. Rewriting the Rules of Metabolic MedicineThe global obesity crisis shows no sign of plateauing. According to the World Health Organization ("WHO"), a reported one billion people globally are currently living with obesity, while type 2 diabetes rates continue to climb across both high-income and developing economies. The WHO further notes that obesity increases the risk of cardiovascular disease, stroke and T2DM, while further research has linked obesity to chronic kidney disease and rising healthcare expenditures, placing substantial and growing pressure on health systems around the world.GLP-1 receptor agonists have rapidly risen to become one of the defining breakthroughs in metabolic medicine. Originally introduced to manage blood glucose levels in diabetes patients, these drugs are now recognized for their capacity to drive meaningful weight reduction and deliver broad improvements in metabolic health. Market leaders Novo Nordisk A/S and Eli Lilly and Company have come to dominate the space through their blockbuster injectable franchises, including Ozempic(R), Wegovy(R), Mounjaro(R) and Zepbound(R).Commercial momentum in this space is increasing. JPMorgan Chase & Co. forecasts that the general obesity drug market could reach $200 billion by 2030 as global adoption expands and indications stretch beyond diabetes and weight management. Additional industry projections suggest GLP-1 therapies are on track to become one of the most commercially successful drug categories ever, with annual sales projections of $150 billion or more by the end of the decade.The industry is already pivoting toward the next generation of incretin therapies, with a focus on improved efficacy, tolerability and patient convenience. Needle-free, including oral, formulas, expanded indications and combination metabolic approaches have emerged as major priorities across the sector. SureNano Science is positioning itself in this scenario as a nimble participant pursuing differentiated innovation through GEP-44, a patented triple agonist peptide licensed from Syracuse University and designed to advance through the U.S. Food and Drug Administration ("FDA") regulatory route.A Next-Gen Candidate Built for Better OutcomesSureNano Science is developing GEP-44 as a patented next-generation metabolic therapy designed to address the limitations of first-generation GLP-1 drugs, positioning this up-and-coming microcap as a small but strategically focused company moving through the FDA process. Unlike traditional GLP-1 agonists, which act on a single receptor pathway, GEP-44 functions as a triple agonist targeting GLP-1 alongside peptide YY receptors Y1 and Y2. This combined mechanism is designed to simultaneously regulate glucose metabolism, reduce appetite and improve tolerability within a single therapeutic molecule.The compound originated at Syracuse University and has generated promising results in preclinical settings. According to research, GEP-44 produced meaningful reductions in food intake and decreased body weight while also enhancing glycemic control in preclinical models. In addition, the compound did not trigger the nausea, malaise and gastrointestinal adverse effects commonly seen with many first-generation GLP-1 therapies, a distinction that could become increasingly significant as patient populations and adherence demands grow.The broader pharmaceutical industry is investing aggressively in incretin therapies that can address tolerability and long-term adherence challenges. PwC reports that the next segment of the obesity drug market will most likely be characterized by expanded indications, more patient-friendly delivery formats and therapies with stronger adherence profiles. This lends itself to a supportive environment for companies pursuing second-generation GLP innovation.Despite being smaller than more-established pharmaceutical players, SureNano Science operates with a lean development model and cost-efficient structure built for flexibility and development speed. The company is involved in substantial research in Australia, where government incentive programs may provide research tax credits of up to 43.5% on qualifying expenditures. Should GEP-44 continue producing favorable results through clinical development, the company could emerge as an attractive acquisition, licensing or partnership candidate within the fast-expanding GLP ecosystem.Market Scale and the Commercial Case for GLP-1 InnovationThe commercial potential tied to GLP-1 therapies is expanding quickly. According to Morgan Stanley, the global GLP-1 market could reach $190 billion by 2035 as patient adoption broadens and therapeutic applications extend into new disease areas. Industry forecasts from BCC Research also forecast significant long-term growth, with the GLP-1 analogue market estimated to reach $268.4 billion by 2030.Patient uptake estimates that between 25 and 30 million Americans could be using GLP-1 therapies by 2030, up from approximately 10 million in 2026. Increasing insurance coverage along with obesity prevalence and growing physician familiarity are all driving the rapid mainstreaming of these treatments.At the same time, the competitive setting is shifting toward the next wave of products. IQVIA calls 2026 the "year of the orals," with oral GLP-1 formulations projected to meaningfully enhance accessibility, compliance and long-term maintenance therapy adoption. The anticipated off-patent expansion of semaglutide across major global markets is also expected to intensify competition while broadening overall patient access.As GEP-44 advances through IND-enabling studies and moves toward eventual phase 1 trials, SureNano Science stands as one of a small number of microcap public companies offering direct exposure to the expanding GLP-1 market. This positioning may represent a meaningful valuation gap relative to large-cap pharmaceutical incumbents and late-stage obesity therapy developers, particularly if the company achieves key clinical and regulatory milestones.Delivery Innovation as a Second Engine of ValueAlongside its core therapeutic development efforts, SureNano Science is also eyeing differentiated drug-delivery technologies designed to improve patient accessibility and long-term adherence. The company's platform strategy includes evaluating oral, sublingual and intranasal delivery approaches that could eventually reduce reliance on injectable administration.Convenience and adherence have emerged as increasingly important competitive dimensions within the GLP-1 market. The dominant therapies today are injection-based, creating barriers for some patients due to administration complexity, refrigeration requirements and long-term compliance challenges. Noninvasive and oral alternatives are widely regarded as representing one of the most significant near-term commercial opportunities in obesity and diabetes treatment.Industry analysts increasingly view delivery innovation as potentially as consequential as efficacy improvements. IQVIA notes that oral obesity therapies could substantially boost long-term maintenance adoption while simplifying supply chains by removing cold-chain requirements, factors that could meaningfully expand patient access in international markets.By combining therapeutic development with delivery innovation, SureNano Science is working to build a vertically integrated metabolic disease platform rather than advancing a single injectable drug candidate. This broader strategy may generate additional long-term optionality and commercial flexibility as the obesity treatment market continues to evolve.Preclinical Data Point to a Meaningful Competitive EdgePreclinical data from SureNano Science suggest that GEP-44 may offer substantive differentiation relative to earlier-generation GLP therapies. According to the company, the compound demonstrated approximately 15% weight loss in preclinical testing, compared with roughly 9% observed with liraglutide, while food intake reductions reached approximately 39% versus around 20% for the comparator.In addition to weight reduction, GEP-44 produced improvements in glycemic control while reportedly avoiding nausea and vomiting during testing. Gastrointestinal side effects remain among the most frequently cited challenges associated with currently marketed GLP-1 therapies and represent a significant driver of discontinuation. Improved tolerability could therefore become a meaningful competitive advantage if these preclinical findings are validated in human studies.The pharmaceutical industry continues to pour resources into next-generation obesity therapies capable of delivering better outcomes and patient experiences. The Pharma Letter reports that obesity drug pipelines are increasingly oriented toward differentiation through combination receptor pathways, improved tolerability profiles, and expanded delivery options as the competitive field intensifies.While GEP-44 remains in preclinical development, these early findings place SureNano Science within a strategically important segment of the obesity treatment landscape. If subsequent studies continue to support these results, the company could establish itself as a distinctive participant in one of the largest and most rapidly expanding therapeutic categories in contemporary healthcare.Exploring Broader Platform Opportunities for Long-Term GrowthBeyond its primary GLP-1 metabolic platform, SureNano Science is also evaluating early-stage opportunities that could expand the long-term scope of its therapeutic and delivery technology portfolio. These discussions include nonbinding opportunities involving ibogaine-related intellectual property concentrated on formulation and delivery technologies.While still exploratory and not considered a core asset at this stage, the initiative reflects a broader strategic aim of building diversified platform capabilities across multiple high-growth therapeutic areas. Scientific and investor interest in ibogaine and related psychedelic-derived therapeutics has grown considerably in recent years, as researchers examine their potential applications in addiction treatment, mental health conditions, and neurological disorders.CNN recently reported on the growing scientific and regulatory attention being directed at ibogaine research, particularly in areas related to opioid addiction and treatment-resistant mental health conditions. The U.S. Food and Drug Administration has also signaled increasing openness to accelerating development pathways for treatments targeting serious mental illnesses and areas of significant unmet medical need.SureNano's interest in formulation and delivery technologies within these emerging areas fits naturally with the company's broader emphasis on drug-delivery innovation and platform versatility. Rather than treating ibogaine-related opportunities as a standalone commercial priority, the company appears to be assessing how specialized delivery technologies and intellectual property could complement its existing capabilities in metabolic therapeutics and nontraditional administration. This kind of optionality may provide incremental long-term strategic value if the regulatory landscape surrounding psychedelic-based therapies continues to evolve.These initiatives remain early stage and are subject to meaningful scientific, clinical and regulatory uncertainty. However, by selectively evaluating expansion opportunities alongside its primary GLP-1 development program, SureNano Science is aligning itself with a broader trend toward diversified therapeutic platforms capable of competing across multiple large and evolving healthcare markets. As pharmaceutical innovation increasingly converges around metabolic health, neuroscience, and advanced delivery technologies, strategic flexibility may prove to be a growing differentiator for emerging biotechnology companies.Advances Continue Across the GLP-1 LandscapeMomentum across the GLP-1 and metabolic disease sector continues to accelerate as leading biotechnology and pharmaceutical companies expand development programs targeting obesity, diabetes, liver disease and broader cardiometabolic conditions. Recent news from the GLP-1 space highlights continued investment in next-generation therapies, late-stage clinical development, strategic partnerships and regulatory progress as the rapidly evolving space remains one of the most closely watched areas in healthcare and biotechnology.Merck & Co. Inc. (NYSE: MRK) expanded into the GLP-1 and obesity-treatment market through an exclusive global licensing agreement with Hansoh Pharma for an investigational oral GLP-1 receptor agonist. Merck stated that the candidate is being developed for cardiometabolic diseases and described the agreement as part of the company's strategy to strengthen its presence in metabolic disorders. The company noted that it will receive exclusive rights outside China to develop, manufacture and commercialize the therapy, reflecting a growing industry focus on oral GLP-1 treatments for obesity and related conditions.AbbVie Inc. (NYSE: ABBV) announced positive topline results from a phase 1 multiple ascending dose study evaluating ABBV-295, its long-acting amylin analog being developed for obesity and metabolic disease treatment. AbbVie reported that ABBV-295 demonstrated "clinically meaningful" body weight reduction ranging from approximately 7.75% to 9.79% over the treatment period, while also showing a "favorable tolerability profile" with no serious adverse events reported. The company emphasized that the data support continued advancement of its metabolic disease pipeline amid increasing interest in next-generation obesity therapies that may complement or compete with GLP-1 drugs.Viking Therapeutics Inc. (NASDAQ: VKTX) reported completion of enrollment in its phase 3 VANQUISH-2 trial evaluating VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity treatment. Viking stated that the study is assessing subcutaneous VK2735 in adults with obesity and type 2 diabetes, while concurrent phase 3 development is also ongoing in broader obesity populations. The company noted that VK2735 is being developed in both oral and injectable formulations for metabolic disorders, underscoring its position in the rapidly expanding GLP-1 obesity-treatment landscape.Altimmune Inc. (NASDAQ: ALT) announced that pemvidutide received FDA Breakthrough Therapy designation for the treatment of MASH, further advancing development of the company's GLP-1/glucagon dual receptor agonist platform. Altimmune stated that pemvidutide has demonstrated improvements in liver fat reduction, weight loss and fibrosis-related measures, while the company plans to initiate a Phase 3 trial evaluating multiple doses over a 52-week treatment period. The announcement reinforces Altimmune's ongoing efforts to position pemvidutide within the broader GLP-1 and metabolic disease sector spanning obesity, liver disease and related cardiometabolic conditions.Collectively, these developments underscore the growing importance of GLP-1-related therapies as companies compete to address some of the world's largest and fastest-growing chronic health challenges. With ongoing advances in oral formulations, combination therapies and expanded metabolic disease applications, the sector continues to attract significant scientific, clinical and investor attention while reshaping the future landscape of obesity and cardiometabolic treatment.For further information about SureNano Science Ltd., visit the SureNano Science profile.About BioMedWireBioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, "Biotech" to 888-902-4192 (U.S. Mobile Phones Only)For more information, please visit https://www.BioMedWire.comDISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/DisclaimerBioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.comBioMedWire is powered by IBN Original: Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5, 2026 7:05 AM
PR Newswire (US) Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity. At ECO, Viking will present a poster highlighting data from its Phase 2 VENTURE-Oral Dosing trial, focusing on key efficacy and safety endpoints, including weight loss and tolerability during the 13-week study. The second poster will highlight the design and enrollment demographics of the ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with obesity or who are overweight and have at least one weight-related comorbidity.Details of the ECO poster presentations are as follows:Title: Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding VENTURE-Oral Study Publication Number: PO4.260Presented by: Karen Modesto, M.D., Vice President, Clinical DevelopmentDate/Time: On display May 12-15, with poster networking session on Thursday, May 14, from 18:00 – 19:15 Turkey TimeLocation: Poster area at Level B5, Istanbul Congress CenterTitle: VANQUISH-1: Phase 3 Trial With Enrollment of a Diverse Population to Test Efficacy of Subcutaneous VK2735 in Adult Participants with Obesity or Overweight with Weight Related ComorbiditiesPublication Number: PO4.278Presented by: Karen Modesto, M.D., Vice President, Clinical DevelopmentDate/Time: On display May 12-15, with poster networking session on Thursday, May 14, from 18:00 – 19:15 Turkey TimeLocation: Poster area at Level B5, Istanbul Congress CenterAbout VK2735VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the treatment of metabolic disorders, including obesity. The compound is being evaluated in both oral and subcutaneous formulations.About GLP-1 and Dual GLP-1/GIP AgonistsActivation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®.About Viking Therapeutics, Inc.Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.Forward-Looking StatementsThis press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin and other receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings.  These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-announces-two-poster-presentations-at-european-congress-on-obesity-eco-2026-302762028.htmlSOURCE Viking Therapeutics, Inc. Original: Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Listen to the webcast

https://ir.vikingtherapeutics.com/webcasts?item=80

Good luck and GOD bless,

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026.

Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 29, 2026

Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health

https://247wallst.com/personal-finance/2026/04/22/biotech-investor-alex-karnal-glp-1-drugs-signal-trillion-dollar-revolution-in-public-health/

Viking Therapeutics drug currently in Phase 3 pivotal trials is a GLP-1 drug in combination with GIP drug compound.

Good luck and GOD bless,

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026April 22, 2026 4:35 PM
PR Newswire (US)

Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026.







The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 29, 2026. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until May 6, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference replay code #2410242. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.About Viking Therapeutics, Inc.Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.



View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-first-quarter-2026-on-april-29-2026-302750792.htmlSOURCE Viking Therapeutics, Inc.

Original: Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

Viking Therapeutics to Participate at Upcoming Investor ConferencesApril 10, 2026 7:30 AM
PR Newswire (US)

SAN DIEGO, April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will attend multiple upcoming investor conferences. 







Details of the company's participation are as follows:Raymond James Biotech/BioPharma Conference 2026
Details: Viking management will participate in 1-on-1 meetings
Conference Date: April 14, 2026
Location: New York, NYPiper Sandler Spring Biopharma Symposium 2026
Details: Viking management will participate in 1-on-1 meetings
Conference Date: April 16, 2026
Location: Boston, MAAbout Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.



View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302739018.htmlSOURCE Viking Therapeutics, Inc.

Original: Viking Therapeutics to Participate at Upcoming Investor Conferences

Oppenheimer sets $100 PT on VKTX oral VK2735 weight loss drug's "potentially impressive launch trajectory."

Not gonna happen, LOL. If you had posted this yesterday, I would have interpreted it an April Fools joke.

$VKTX should buy $BYND "Why This Could Be a Winning Pivot

- Plant-based meat is shrinking; beverages are growing.

- Functional drinks are projected to keep expanding.

- GLP-1 users are seeking **high-protein, low-calorie** options — exactly Beyond’s lane.

- Beyond’s brand already stands for “better-for-you protein,” making the transition natural."

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735March 26, 2026 7:05 AM
PR Newswire (US)

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 DiabetesSAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.







The Phase 3 VANQUISH-2 study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks. The trial enrolled approximately 1,000 adults with type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2). Enrolled patients have been randomized to one of four weekly treatment arms: VK2735 7.5 mg, 12.5 mg, 17.5 mg, and placebo. The primary endpoint of the trial is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment. Secondary and exploratory endpoints are evaluating a range of additional safety and efficacy measures, including the percentage of patients who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction. The study includes a 52-week extension period allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period."Completing enrollment in the VANQUISH-2 study is an important milestone for Viking as it is the second of our two registration studies to be fully enrolled," said Brian Lian, Ph.D., chief executive officer of Viking. "As with the VANQUISH-1 study, we are happy to see a study of this size enroll quickly, which we believe speaks to the enthusiasm for new obesity treatments beyond those currently available. We look forward to completing the VANQUISH studies in 2027."Concurrently, Viking is conducting the Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients who have obesity or are overweight. Enrollment in VANQUISH-1 was completed in November 2025. Viking is also evaluating VK2735 in a Phase 1 study evaluating a range of potential maintenance dosing regimens. The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints are assessing change in body weight from baseline, as well as change in body weight following the transition to maintenance dosing. The company expects to report the results from this study in the third quarter of 2026.In 2024, Viking announced positive results from the Phase 2 VENTURE study of VK2735 in obesity. This trial successfully achieved its primary and secondary endpoints, with subjects receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. After 13 weekly subcutaneous doses, subjects receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with the majority of observed adverse events (AEs) being reported as mild or moderate. Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo.About GLP-1 and Dual GLP-1/GIP AgonistsActivation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®.About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.Forward-Looking StatementsThis press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements except as required by law.



View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-announces-completion-of-enrollment-in-phase-3-vanquish-2-trial-of-vk2735-302725563.htmlSOURCE Viking Therapeutics, Inc.

Original: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
Each of these companies could benefit from this high-growth market over time.

fool.com/investing/2026/03/...

Good luck and GOD bless,

Gigantic market is going to mean a lot of competition. We just need the phase 3 trials of the subcutaneous VK2735 to work out.

They have a tremendous amount of competition.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $93.00 average price target, a 189.5% upside from current levels. In a report issued on February 25, BTIG also maintained a Buy rating on the stock with a $125.00 price target.

https://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/606648/analysts-are-bullish-on-these-healthcare-stocks-viking-therapeutics-vktx-xencor-xncr/

Good luck and GOD bless,

Viking Therapeutics to Participate at Upcoming Investor ConferencesMarch 5, 2026 4:03 PM
PR Newswire (US)

SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. 







Details of the company's participation are as follows:Leerink Partners Global Healthcare Conference 2026
Details: Viking management will participate in a fireside chat and in 1-on-1 meetings
Conference Date: March 8-11, 2026
Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern on Tuesday, March 10, 2026
Location: Miami, FL2026 Jefferies Biotech on the Beach Summit
Details: Viking management will participate in 1-on-1 meetings
Conference Dates: March 10-11, 2026
Location: Miami, FLA live webcast of the Leerink presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.  Additionally, a replay of the webcast will be available on the Viking website following the conference. About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.



View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302705936.htmlSOURCE Viking Therapeutics, Inc.

Original: Viking Therapeutics to Participate at Upcoming Investor Conferences

What about NVO? They lost Metsera bidding war, and they seem to need a boost in this space...

That must be very old copy. PFE is no longer a plausible suitor since they acquired Metsera.

Viking Therapeutics (VKTX) is subject to intense acquisition speculation, primarily driven by its promising GLP-1/GIP obesity candidate, VK2735, with Pfizer frequently mentioned as a potential acquirer. Rumors suggest a high-premium buyout, possibly exceeding $7–$9 billion. Analysts maintain high price targets, driven by strong phase 2 data and upcoming phase 3 trials.

Good luck and GOD bless,

Is Viking Therapeutics Stock Really Going to $125?

https://www.aol.com/articles/viking-therapeutics-stock-really-going-204300023.html

Good luck and GOD bless,

Novo Nordisk shares extend losses following analyst downgrades

February 24, 2026 6:06 AM
IH Market News


Novo Nordisk (NYSE:NVO) continued to face selling pressure after JPMorgan downgraded the stock to Neutral from Overweight, citing disappointing late-stage REDEFINE-4 trial results for its obesity treatment CagriSema, which indicated weaker competitiveness compared with Eli Lilly’s (NYSE:LLY) Zepbound.

The bank also reduced its price target to 250 Danish crowns from 350, while analysts at Deutsche Bank and Kepler Cheuvreux similarly lowered their ratings on the shares.

Novo Nordisk stock fell about 3.61% in Copenhagen trading, last changing hands at 243.60 DKK per share.

JPMorgan analyst Richard Vosser said the latest trial outcomes revealed a less compelling weight-loss profile compared with Lilly’s Zepbound in obesity treatment, along with a more modest glucose-lowering effect in patients with Type 2 diabetes, prompting revisions to the firm’s outlook.

Vosser noted that earlier forecasts had already assumed limited market penetration for CagriSema following previous trial data, but he now anticipates “a more challenging uptake for the product given inferiority to Zepbound.”

Consequently, JPMorgan reduced its CagriSema revenue projections by 40%–63% for the 2027–2030 period and lowered amycretin estimates by 1%–23% to account for weaker anticipated pricing. These revisions resulted in cuts of 2%–16% to group sales forecasts for 2026–2030 and reductions of 2%–17% in adjusted earnings per share expectations.

The analysts now estimate Novo’s earnings outlook for 2026–2030 to be between 5% and 21% below Bloomberg consensus forecasts, with projected EPS growth broadly aligned with other large-cap European pharmaceutical peers.

Vosser added that the CagriSema profile “seems hard to recover from inferiority result in REDEFINE 4,” despite weight-loss results of roughly 20%, which still exceed Wegovy but fall short of Zepbound’s 23%.

He maintained a more positive long-term view on amycretin, particularly its potential as an oral therapy, though he cautioned that investor sentiment will likely hinge on Phase III trial results expected between 2028 and 2029.

In a separate research note, Barclays adopted a more optimistic short-term stance on the rollout of Oral Wegovy, saying early prescription data are “encouraging.” The bank reported that Week 7 prescriptions reached roughly 48,000, representing a 12% week-on-week increase, while daily TRx figures showed “a strong ramp continues.”

Viking Therapeutics Might Be a Weight-Loss Drug Moon Shot in the Making.

finance.yahoo.com/news/got-...

Good luck and GOD bless,

Here is some actual news instead of baseless rumors:
Eli Lilly shares gain after Novo Nordisk obesity drug falls short in trial

February 23, 2026 11:23 AM
IH Market News


Shares of Eli Lilly (NYSE:LLY) rose 2.8% to $1,037 in premarket trading Monday after rival Novo Nordisk (CSE:NOVOb) reported that its experimental obesity treatment CagriSema failed to meet a key clinical trial objective.

Novo Nordisk said the study did not demonstrate that CagriSema was non-inferior to Eli Lilly’s Tirzepatide in reducing body weight. Trial data showed patients receiving CagriSema achieved an average weight reduction of 23% over 84 weeks, compared with 25.5% for Tirzepatide.

The Danish pharmaceutical company plans to launch a higher-dose trial of CagriSema in the second half of 2026, with a decision from the U.S. Food and Drug Administration expected later that year.

U.S.-listed shares of Novo Nordisk dropped 14.8% to $40.41 in premarket trading following the announcement.

J.P.Morgan said that although CagriSema could eventually provide Novo Nordisk with a more competitive product, it may struggle to capture market share from Eli Lilly. The bank noted that Eli Lilly’s Zepbound is already firmly positioned in the market after the latest results and expects the company to maintain a longer runway for market share expansion beyond 2026.

Eli Lilly stock price



Original: Eli Lilly shares gain after Novo Nordisk obesity drug falls short in trial

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds

https://finance.yahoo.com/news/3-reasons-viking-therapeutics-stock-103000062.html

Good luck and GOD bless,

Judging from today's action, you might be on to something....but today's move is more likely bound to NOVO's recent results in CagriSema, IMHO.

What are your sources?

From what I hear negotiations are currently in progress!!!

Good luck and GOD bless,

Is Viking Therapeutics Stock Really Going to $125?

https://finance.yahoo.com/news/viking-therapeutics-stock-really-going-204300062.html

Good luck and GOD bless,

Accessible Health Platforms Gain Scale Across $6T Health and Wellness MarketFebruary 13, 2026 11:26 AM
PR Newswire (US)

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.VANCOUVER, BC, Feb. 13, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual consumer spending, underpinned by rising demand for functional products that deliver measurable outcomes beyond basic nutrition[1]. At the same time, the FDA's updated "Healthy" labeling framework and stricter clean-label regulations are reshaping how brands formulate and position consumer health products, pushing innovation toward sugar-free, preservative-free, and portable delivery systems[2]. Five companies operating along that accessibility curve include Doseology Sciences (CSE: MOOD), Amneal Pharmaceuticals (NASDAQ: AMRX), Prestige Consumer Healthcare (NYSE: PBH), Viking Therapeutics (NASDAQ: VKTX), and Insulet (NASDAQ: PODD).A recent Global Wellness Summit forecast identifies personalized oral delivery and functional reformulation as defining themes for 2026, as consumers prioritize convenience, clinical credibility, and precise dosing[3]. That convergence of wellness innovation and broader healthcare accessibility is channeling capital toward platforms built around scalable, consumer-centric health delivery[4].Doseology Sciences Inc. (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) recently launched pilot production of caffeine-based energy pouches in January 2026, marking the Feed That Brain brand's entry into the fast-expanding oral pouch category. Based in Kelowna, British Columbia, Doseology Sciences is producing nicotine-free pouches that deliver measured caffeine doses in a compact, portable format, drawing on the same consumer shift that turned tobacco-free nicotine pouches into a multibillion-dollar segment.The pilot pouches skip the sugar, carbonation, and liquid volume found in conventional energy drinks. A direct-to-consumer test phase is planned to collect customer feedback and operational data ahead of any broader commercial launch."This pilot reflects a disciplined and intentional approach to evaluating new product formats within our platform," said Tim Corkum, President and COO of Doseology Sciences. "Feed That Brain brings a strong foundation in functional product design, and this initiative allows us to assess caffeine-based, pouch-format energy delivery under a measured and compliant framework."The energy pouch program grew out of Doseology Sciences' August 2025 acquisition of the Feed That Brain brand for $400,000, paid entirely through stock issuance. Feed That Brain, a Toronto-based cognitive health label founded by Forbes-recognized entrepreneur Rena R. Dempsey, built its reputation on functional gummies and nootropic supplements designed to support mental performance.Doseology Sciences also secured Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units. Mimran co-founded Alfred Sung, founded Club Monaco (later acquired by Ralph Lauren), and created the Joe Fresh retail brand. He cited the company's product development process and attention to regulatory compliance as reasons for joining.Two large market tailwinds support the strategy. Grand View Research projects the global energy drinks market will grow from $79.4 billion in 2024 to $125.1 billion by 2030. The nicotine pouch segment is forecast to climb from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% annual growth rate. Rising consumer concern over sugar intake and beverage overconsumption continues to push demand toward alternative caffeine delivery methods.Doseology Sciences currently distributes Gummies and Collagen products under the Feed That Brain brand across close to 500 Canadian retail locations. Its U.S. subsidiary, Doseology USA Inc., established earlier this year, is working on pouches that blend caffeine with nootropics and adaptogens. The leadership team now includes CEO Chris Jackson, President and COO Tim Corkum, and Strategic Go-to-Market Advisor Patrick Sills.CONTINUED... Read this and more news for Doseology Sciences at:https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/Amneal Pharmaceuticals (NASDAQ: AMRX) introduced a new brand identity reflecting its evolution into a diversified global biopharmaceutical leader, anchored by a refreshed logo symbolizing the trust placed in healthcare providers and the real-world impact of each prescription. The company now delivers more than 160 million prescriptions annually across a portfolio of over 290 medicines."As Amneal has grown and diversified, our brand needed to evolve with us," said Chirag Patel, Co-Founder and Co-CEO of Amneal Pharmaceuticals. "This new brand reflects who we are today and where we are headed. It signals our ambition, our capabilities, and our unwavering focus on expanding access to medicines that make a meaningful difference in people's lives."Amneal Pharmaceuticals plans to introduce its Accessibility Index later this year, a platform designed to demonstrate real impact on affordability, availability, and innovation across its portfolio spanning complex generics, injectables, biosimilars, and specialty therapies.TheraTears, a subsidiary of Prestige Consumer Healthcare (NYSE: PBH), expanded its dry eye portfolio with two new products launching nationwide in February 2026: Eyelid Cleansing Wipes and Dry & Tired Preservative Free Lubricant Eye Drops. The preservative-free drops contain twice the hydrating ingredient of TheraTears' original formula and target consumers experiencing screen-related eye fatigue.The Eyelid Cleansing Wipes are formulated for gentle daily use with a non-stinging formula that removes irritants aggravating dry eye symptoms. Both products will be available at Amazon, Walgreens, and Walmart as part of the ophthalmologist-created brand's growing family of eye care solutions under Prestige Consumer Healthcare.Viking Therapeutics (NASDAQ: VKTX) reported fourth quarter and full-year 2025 financial results highlighting rapid progress across its obesity portfolio, ending the year with $706 million in cash to fund near-term catalysts including Phase 3 VANQUISH trials for subcutaneous VK2735. VANQUISH-1 enrollment exceeded 4,500 patients ahead of schedule, while VANQUISH-2 nears full enrollment."The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio," said Brian Lian, Ph.D., CEO of Viking Therapeutics. "We also expect to file an IND for our novel amylin agonist this quarter, expanding our obesity franchise."Viking Therapeutics plans to advance oral VK2735 into Phase 3 development in the third quarter of 2026, with maintenance dosing study results also expected in that period. The dual GLP-1/GIP agonist demonstrated up to 14.7% weight loss from baseline in its Phase 2 VENTURE trial.Insulet (NASDAQ: PODD) launched its Omnipod 5 Automated Insulin Delivery System across Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, bringing the tubeless wearable pump's global availability to 19 countries. The company simultaneously debuted Omnipod Discover, a proprietary data analytics platform designed to simplify glucose and insulin delivery insights for users and healthcare providers."We're proud to bring Omnipod 5 to a region where the unmet need is great," said Pat Crannell, Senior Vice President and International General Manager of Insulet. "It is even more meaningful and impactful with the inaugural introduction of Omnipod Discover, which simplifies data management and helps us create a world where diabetes demands less, every day."Insulet plans to launch Omnipod 5 in Spain later in 2026, followed by Greece and Croatia in the first half of 2027. Omnipod Discover will roll out to additional international markets after the Middle East introduction.Article Source: https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/ CONTACT:Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). "). This article is being distributed for Maynard Communications ("MAY"), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Doseology Sciences. Inc. advertising or digital media, but expects to be paid a fee from ("MAY"). There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Doseology Sciences Inc.; this is a paid advertisement, we currently own shares of Doseology Sciences Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:1.   https://www.precedenceresearch.com/functional-beverages-market2.   https://www.mordorintelligence.com/industry-reports/global-functional-food-market3.   https://globalwellnessinstitute.org/press-room/press-releases/global-wellness-summit-releases-10-wellness-trends-for-2026/4.   https://insights.citeline.com/hbw-insight/perspectives/consumer-health-and-wellness-market-outlook-what-trends-will-impact-self-care-in-2026-T7WQJYMDZJE4FLRJAEHVIT7REE/Logo - https://mma.prnewswire.com/media/2840019/5798142/Equity_Insider_Logo.jpg 





View original content to download multimedia:https://www.prnewswire.com/news-releases/accessible-health-platforms-gain-scale-across-6t-health-and-wellness-market-302687851.html

Original: Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market

Viking Therapeutics jumps nearly 12% on plans to move oral obesity drug into Phase 3February 12, 2026 9:48 AM
IH Market News
Viking Therapeutics Inc. (NASDAQ:VKTX) surged 11.63% after unveiling plans to advance its experimental oral obesity treatment, VK2735, into Phase 3 trials in the third quarter of this year.The biotech firm said late-stage study data showed that once-daily dosing of the oral VK2735 tablet led to average weight loss of up to 12.2% after 13 weeks. Viking emphasized that having both oral and injectable versions of VK2735 sets it apart in the competitive obesity drug market, noting that “no other dual or triple agonist is currently available in both formulations.”Wall Street reacted favorably to the update.Raymond James pointed to the broader market opportunity, stating, “In our view, the sizable opportunity for the oral VK2735 program is highlighted by the recently announced, impressive early launch metrics (~50k scripts in the first three weeks) for Novo’s oral Wegovy, which reached the U.S. market in early January.”Leerink also struck an optimistic tone, writing, “Overall, we remain encouraged by VKTX’s clinical execution and continue to see both fundamental and strategic value for the company’s potentially best-in-class portfolio of obesity and metabolic disease programs. We expect VKTX’s maintenance trial will provide optionality to leverage both ’2735 formulations to drive robust initial weight loss (i.e., subcutaneous induction) followed by a convenient, well-tolerated maintenance regimen (i.e., lower and/or less-frequently dosed subcutaneous or oral).”Truist underscored the importance of the development in a client note, saying, “4Q25 update was notable for successful EOP2 mtg with plans to start Ph3 study of oral VK2735 in 3Q26. Given successful launch of Wegovy pill, which represents one of, if not the best drug launch in history, we think oppty of oral VK2735 is woefully underappreciated.”The planned Phase 3 move marks a key milestone for Viking as it seeks to position VK2735 among next-generation obesity therapies.Viking Therapeutics stock price

Original: Viking Therapeutics jumps nearly 12% on plans to move oral obesity drug into Phase 3

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateFebruary 11, 2026 4:16 PM
PR Newswire (US)

Conference call scheduled for 4:30 p.m. ET todayOral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided an update on its clinical pipeline and other corporate developments.







Highlights from the Quarter and Year Ended December 31, 2025, and Other Recent Events:"The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio," stated Brian Lian, Ph.D., chief executive officer of Viking.  "In June, the company initiated the Phase 3 VANQUISH clinical program evaluating the subcutaneous formulation of VK2735, a dual agonist of the GLP-1 and GIP receptors, for obesity.  We announced completion of enrollment in VANQUISH-1 in the fourth quarter and expect to complete enrollment in VANQUISH-2 later this quarter.  In 2025 the company also announced positive top-line results from its Phase 2 VENTURE-Oral dosing trial of the tablet formulation of VK2735 in obesity.  Following feedback from an end-of-Phase 2 meeting with the FDA, we plan to advance oral VK2735 into Phase 3 development in 3Q26.  Based on exciting early data suggesting the potential for maintenance dosing with VK2735, in the fourth quarter we initiated a study designed to evaluate monthly subcutaneous dosing, daily oral dosing, and weekly oral dosing.  This trial will provide data to potentially further differentiate VK2735 as the only dual agonist molecule with the potential to dose monthly or to allow transition from subcutaneous to oral administration for weight maintenance.  This study is fully enrolled and we look forward to announcing the results in the third quarter of 2026.  We also expect to file an IND for our novel amylin agonist this quarter, expanding our obesity franchise.  During the year Viking continued building the foundation to support commercial activities by entering into a comprehensive manufacturing and supply agreement for VK2735 and expanding our commercial depth to prepare for success.  Throughout these activities we have continued to exercise fiscal discipline and maintain a strong balance sheet, which will allow us to meet key milestones in the quarters ahead.  We expect 2026 to be another exciting and productive year and look forward to providing updates along the way."Pipeline and Recent Corporate HighlightsPhase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Fully Enrolled Ahead of Schedule, VANQUISH-2 Nearing Full Enrollment. VK2735 is a wholly owned long-acting dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, for the potential treatment of obesity and other metabolic disorders. The company previously announced positive top-line data from its Phase 2 VENTURE study of VK2735 in adults with obesity. This study demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% after 13 weekly doses. The VENTURE study also showed VK2735 to be safe and well tolerated through 13 weeks of dosing, with the majority of treatment emergent adverse events characterized as mild or moderate. Adverse events generally occurred early in the course of treatment, resolved quickly, and were primarily related to the expected gastrointestinal effects resulting from activation of the GLP-1 receptor. In June 2025, following an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the company initiated the VANQUISH Phase 3 registration program. The VANQUISH program consists of two trials evaluating VK2735: one in adults with obesity (VANQUISH-1) and one in adults with obesity and type 2 diabetes (VANQUISH-2). Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks. The VANQUISH-1 study was designed to target enrollment of approximately 4,500 patients, and the VANQUISH-2 study is targeting enrollment of approximately 1,100 patients. Participants in each of these trials will be randomized to weekly VK2735 treatment arms of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.The primary endpoint of the VANQUISH trials is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures, including the percentage of patients who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction. Each study will also include a one-year extension allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period, including patients receiving placebo during the initial portion of trial.In November 2025 the company announced completion of enrollment in the VANQUISH-1 study. The trial enrolled more than 4,500 patients, exceeding the original enrollment target, ahead of schedule. The company believes the rapid pace of enrollment observed in the VANQUISH program demonstrates the significant continued enthusiasm among investigators, clinicians and patients for the VK2735 program. Enrollment in the VANQUISH 2 study is continuing and the company expects to complete enrollment in 1Q26.Phase 2 VENTURE Data Highlighted in Presentations at ObesityWeek 2025 and Published in Peer-Reviewed Journal, Obesity. The effects of weekly VK2735 on certain cardiometabolic parameters that were observed in the VENTURE study were highlighted in a poster presentation at the 2025 ObesityWeek conference in November. The results demonstrated that patients receiving VK2735 experienced improvements in metabolic syndrome and prediabetic status compared with patients receiving placebo. In addition, in January 2026 the full results of the VENTURE study were the subject of a publication titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," published in Obesity, the peer-reviewed journal of The Obesity Society. This publication can be accessed online at: https://onlinelibrary.wiley.com/doi/10.1002/oby.70106. The ObesityWeek presentation and Obesity publication highlight VK2735's promising efficacy, tolerability, and broader impact on improved cardiometabolic status after a relatively short 13 week treatment window.Oral VK2735 to Advance into Phase 3 Trials, Expected to Begin 3Q26. In addition to the development of a subcutaneous formulation, Viking is also advancing an oral tablet formulation of VK2735. The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations. The successful development of both a tablet and a subcutaneous injection may represent an attractive option for those who prefer to initiate treatment with an oral therapy, or for those seeking to maintain the weight loss they have already achieved with an injectable therapy. Using the same active ingredient in both formulations may reduce the risk of unexpected side effects compared with switching between therapies that do not share the same active agent.The company's prior Phase 1 and Phase 2 studies evaluating the oral tablet formulation of VK2735 successfully achieved their objectives. Viking's Phase 1 study demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2% after 28 days of daily dosing. The initial weight loss observed in the Phase 1 study also showed encouraging durability, with up to 8.3% reduction in body weight from baseline observed at follow-up visits through Day 57, four weeks after the last dose was administered. The study demonstrated encouraging safety and tolerability through 28 days of once-daily dosing, at doses up to and including 100 mg, with the majority of observed treatment emergent adverse events (TEAEs) reported as mild or moderate, with most reported as mild. The company's Phase 2 VENTURE-Oral Dosing study also successfully achieved its primary and secondary endpoints, with impressive reductions in body weight observed, as well as an encouraging safety and tolerability profile. This study was a randomized, double-blind, placebo-controlled multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics and weight loss efficacy of VK2735 dosed as an oral tablet once daily for 13 weeks. The primary endpoint of the study was the percent change in body weight from baseline after 13 weeks of treatment.In the third quarter of 2025, the company announced positive top-line results from the VENTURE-Oral Dosing study, with statistically significant reductions in body weight observed, along with promising safety and tolerability. Participants receiving once daily doses of the oral tablet formulation of VK2735 demonstrated reductions in mean body weight after 13 weeks, ranging up to 12.2% from baseline. Weight loss was progressive at all doses through the course of the study. Statistically significant differences compared to both baseline and placebo were observed for all doses >15 mg starting at Week 1 and continuing throughout the 13-week treatment period. All doses of VK2735 >15 mg also demonstrated statistically significant differences relative to placebo on the key secondary endpoint assessing the proportion of subjects demonstrating at least 5% and 10% weight loss. Up to 97% of subjects in the VK2735 treatment groups achieved ≥5% weight loss, compared with 10% for placebo, and up to 80% of subjects in VK2735 treatment groups achieved ≥10% weight loss, compared with 5% for placebo.The VENTURE-Oral Dosing study included an exploratory dosing cohort designed to assess weight loss maintenance. In this cohort, participants were rapidly titrated to 90 mg daily doses. After four weeks of daily dosing at 90 mg, participants were down-titrated to 30 mg daily doses and maintained at 30 mg daily for seven weeks. Weight loss in this cohort was shown to be rapid and progressive through the 90 mg treatment period and was further extended following the transition to 30 mg daily doses. The observed results suggest that effective weight maintenance may be possible at doses

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026February 4, 2026 4:05 PM
PR Newswire (US)

Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026.







The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, February 11, 2026. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until February 18, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference replay code #3246362. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.



View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2025-on-february-11-2026-302678194.htmlSOURCE Viking Therapeutics, Inc.

Original: Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

https://finance.yahoo.com/news/viking-therapeutics-announces-publication-results-120000338.html

Good luck and GOD bless,

Interesting, thanks for sharing. They need to prove their compounds are at least competitive in the tolerability aspect. After that they'll probably be acquired, IMHO.

Not sure why in light of the following statement by the CEO that the stock is dropping. Maybe no confidence that Viking is a target:

"REUTERS
Jan-12-2026 7:19 p.m. ET
By Puyaan Singh
Jan 12 (Reuters) - Weight-loss drug developer Viking Therapeutics (VKTX) CEO said on Monday that strategic interest in weight-loss drug deals is broader than it appears, as ?drugmakers seek to tap into the potential $150 billion market.
Pharmaceutical companies ?are targeting the booming weight-loss drug market, which ‍analysts estimate could exceed $150 billion annually ?by the ?end of the decade.
Key growth drivers include expanded clinical applications, ?wider patient adoption, improved drug ?manufacturing capacity, and a pipeline of next-generation therapies.
"I think the interest is probably ?broader than is ‍visible ... more ?parties sort of circling around the space and very intrigued," Viking CEO Brian Lian said ‍at the J.P. Morgan healthcare conference.
Last November, Pfizer (PFE) acquired Metsera for $10 billion, gaining a foothold in the fast-growing market following a fierce bidding war with Novo Nordisk.
Lian said pharmaceutical companies ?are ‍trying to determine how to approach obesity treatments - whether to pursue a new drug ?compound in early-stage development, which could come at a lower price point, or opt for "something proven", which may be more expensive.
During Viking's third-quarter earnings call in October, Lian said the company is open to ?outside interest, which he would prefer, but emphasized that the drug developer is prepared to go alone if necessary.
(Reporting by ‍Puyaan Singh in Bengaluru; Editing by Sherry Jacob-Phillips)"

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

finance.yahoo.com/news/viki...

Good luck and GOD bless,

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
PR Newswire
Mon, January 5, 2026 at 4:03 PM EST

https://finance.yahoo.com/news/viking-therapeutics-present-44th-annual-210300597.html

Good luck and GOD bless,

But looks like NVO's low ball pricing announced today had hit VKTX's sp like a ton of bricks. 

FDA approval of oral Wegovy was never in doubt. Oral Wegovy is not a new drug, but rather a rebranding of NVO's Rybelsus (approved in 2019 for T2D but not for weight loss) with higher recommended dosing:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177094520

OKay. Novo got approval for their GLP-1 pill. How bad is that for Viking?

Viking A Top M&A Pick—Again
Always a bridesmaid, never a bride. M&A chatter for Viking Therapeutics has been happening for years, as the biotech plays in one of the hottest biopharma spaces: obesity. But of course, with Metsera heightening excitement, the company is back on analysts’ lists as a potential buyout target.

“Overall, we continue to believe that Viking’s obesity franchise offers a unique set of attractive qualities that will be viewed favorably in the lens of big pharma from an M&A perspective, especially given the recent business development fervor,” William Blair wrote in mid-November, just under a week after the Metsera deal closed. The firm previously named Viking as its top acquisition pick for 2025.

Viking is pushing ahead quickly, a feat for a small biotech that has been made possible by the consumer excitement around weight loss medications. Its lead asset is VK2735, a dual GLP-1/GIP receptor agonist under development in bothsubcutaneous and oral formulations. Enrollment of 4,650 patients who are obese or overweight in the Phase III VANQUISH-1 trial is already complete. Results should arrive around mid-2027.

“We commend management for developing the asset at a torrid pace and moving into Phase III trials roughly three years after starting the Phase I trial,” William Blair wrote.

Should a deal never materialize, the firm believes Viking shareholders should still benefit as management plows ahead solo. But VK2735 would be better off with more experienced hands as the direct-to-consumer push has been hard to navigate even for market leaders Lilly and Novo, the analysts wrote.

“While Viking is advancing VK2735 directly to a Phase III program, given the unprecedented market opportunity in obesity, we believe that the value of VK2735 will ultimately be maximized in the hands of a Big Pharma, which could best navigate the rebate/discount-driven reimbursement landscape.”

Maybe 2026 will be Viking’s M&A year.

https://www.biospace.com/business/6-biotechs-that-could-be-big-pharmas-next-m-a-target

1 Bold Prediction for Viking Therapeutics in 2026

Key Points

Takeover activity has been high lately in the intensely competitive anti-obesity drug space.
Viking's pipeline may contain plenty of hidden value that a larger company might release.
10 stocks we like better than Viking Therapeutics ›

Upstart biotech company Viking Therapeutics (NASDAQ: VKTX) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its product pipeline. Here's why major drugmakers might now be drawn to buying this relatively small player in the pharmaceutical industry.


Takeover activity is high in the industry

The recent bidding war between Pfizer and Novo Nordisk over Metsera (won by Pfizer) highlights the attraction of buying smaller companies with pipelines that have obesity treatments. Given that Viking has a dual GLP-1/GIP agonist, VK2735, in late-stage trials in both oral and subcutaneous (under-the-skin) forms, it's potentially a prime target.


Viking's pipeline might be more attractive than the market thinks

Investors were shocked in August when Viking's Venture phase 2 results for VK2735, an oral anti-obesity candidate, revealed a relatively high discontinuation rate of 20% due to adverse events (usually gastrointestinal) in the treatment group. It was disappointing, but there was no issue with efficacy, as evidenced by a 12.2% weight loss after just 13 weeks in the treatment group.


Additionally, the cohort may have had some relatively unfavorable characteristics, as 13% of the placebo group also dropped out due to an adverse event. That's a higher rate than the discontinuation rate due to adverse events of 10.3% for Eli Lilly's (NYSE: LLY) oral GLP-1 drug, orforglipron, in its phase 3 Attain-1 trial in treating obesity. Furthermore, Lilly's phase 3 Attain-1 trial lasted 72 weeks, whereas Viking's phase 2 Venture trial lasted 13 weeks.

A graph shows an arrow diving and then rebounding, with a tiny investor pointing up at the inflection point.
Image source: Getty Images.
It's easy to conclude that oral VK2735 has safety issues, but a larger company might not share the same view. The Venture trial was relatively short, and the titration rate may have been too aggressive for patients to adjust. Furthermore, the phase 1 safety data for oral VK2735 in treating obesity were exemplary.


Finally, Viking has already initiated a trial using oral VK2735 as a maintenance dose in combination with subcutaneous VK2735. Clinical trials are complex, generating vast amounts of data, and larger companies are often better equipped to manage them. Don't be surprised if a larger rival takes a look at acquiring Viking Therapeutics in 2026.

https://finance.yahoo.com/news/1-bold-prediction-viking-therapeutics-183500838.html

Good luck and GOD bless,

PFE was already ruled out as a suitor when they acquired Metsera (#msg-176942527).

Wonder how bad this is for us: PFE not a suitor
https://www.businesswire.com/news/home/20251209536063/en/Pfizer-Enters-into-Exclusive-Collaboration-and-License-Agreement-with-YaoPharma

Viking Therapeutics (VKTX) had its Relative Strength (RS) Rating upgraded from 75 to 81 Thursday.

IBD's proprietary rating measures share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.

History shows that the market's biggest winners typically have an 80 or better RS Rating in the early stages of their moves.

https://www.investors.com/ibd-data-stories/viking-therapeutics-meets-80-plus-relative-strength-rating-benchmark/

Good luck and GOD bless,

Viking Therapeutics: Prepping For A Critical 2026

https://seekingalpha.com/article/4850936-viking-therapeutics-prepping-for-a-critical-2026

Good luck and GOD bless,

That's what I'm banking on! Meanwhile, pps still appreciating.